122 related articles for article (PubMed ID: 34182244)
1. Effect of mycophenolic acid and tacrolimus on the incidence of infectious complications after kidney transplantation.
Vnučák M; Graňák K; Skálová P; Laca Ľ; Mokáň M; Dedinská I
Int Immunopharmacol; 2021 Sep; 98():107908. PubMed ID: 34182244
[TBL] [Abstract][Full Text] [Related]
2. An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients.
Sommerer C; Suwelack B; Dragun D; Schenker P; Hauser IA; Witzke O; Hugo C; Kamar N; Merville P; Junge M; Thaiss F; Nashan B;
Kidney Int; 2019 Jul; 96(1):231-244. PubMed ID: 31027892
[TBL] [Abstract][Full Text] [Related]
3. Early Immunosuppressive Exposure of Enteric-Coated-Mycophenolate Sodium Plus Tacrolimus Associated with Acute Rejection in Expanded Criteria Donor Kidney Transplantation.
Ding CG; Jiao LZ; Han F; Xiang HL; Tian PX; Ding XM; Pan XM; Tian XH; Li Y; Zheng J; Xue WJ
Chin Med J (Engl); 2018 Jun; 131(11):1302-1307. PubMed ID: 29786042
[TBL] [Abstract][Full Text] [Related]
4. Mycophenolic Acid Trough Concentration and Dose Are Associated with Hematologic Abnormalities but Not Rejection in Kidney Transplant Recipients.
Jung HY; Lee S; Jeon Y; Choi JY; Cho JH; Park SH; Kim YL; Kim HK; Huh S; Won DI; Kim CD
J Korean Med Sci; 2020 Jun; 35(24):e185. PubMed ID: 32567256
[TBL] [Abstract][Full Text] [Related]
5. Safety profile comparing azathioprine and mycophenolate in kidney transplant recipients receiving tacrolimus and corticosteroids.
Cristelli MP; Tedesco-Silva H; Medina-Pestana JO; Franco MF
Transpl Infect Dis; 2013 Aug; 15(4):369-78. PubMed ID: 23701592
[TBL] [Abstract][Full Text] [Related]
6. Limits to intensified mycophenolate mofetil dosing in kidney transplantation.
Kiberd BA; Lawen J; Daley C
Ther Drug Monit; 2012 Dec; 34(6):736-8. PubMed ID: 23007746
[TBL] [Abstract][Full Text] [Related]
7. Does reduction in mycophenolic acid dose compromise efficacy regardless of tacrolimus exposure level? An analysis of prospective data from the Mycophenolic Renal Transplant (MORE) Registry.
Langone A; Doria C; Greenstein S; Narayanan M; Ueda K; Sankari B; Pankewycz O; Shihab F; Chan L
Clin Transplant; 2013; 27(1):15-24. PubMed ID: 22861144
[TBL] [Abstract][Full Text] [Related]
8. Incidence and risk factors associated with cytomegalovirus infection after the treatment of acute rejection during the first year in kidney transplant recipients receiving preemptive therapy.
Felipe C; Ferreira AN; de Paula M; Viana L; Cristelli M; Medina Pestana J; Tedesco-Silva H
Transpl Infect Dis; 2019 Dec; 21(6):e13106. PubMed ID: 31081566
[TBL] [Abstract][Full Text] [Related]
9. Conversion from tacrolimus-mycophenolate mofetil to tacrolimus-mTOR immunosuppression after kidney-pancreas transplantation reduces the incidence of both BK and CMV viremia.
Knight RJ; Graviss EA; Nguyen DT; Kuten SA; Patel SJ; Gaber L; Gaber AO
Clin Transplant; 2018 Jun; 32(6):e13265. PubMed ID: 29676018
[TBL] [Abstract][Full Text] [Related]
10. Use of De Novo mTOR Inhibitors in Hypersensitized Kidney Transplant Recipients: Experience From Clinical Practice.
Cucchiari D; Molina-Andujar A; Montagud-Marrahi E; Revuelta I; Rovira J; Ventura-Aguiar P; Piñeiro GJ; De Sousa-Amorim E; Esforzado N; Cofán F; Torregrosa JV; Ugalde-Altamirano J; Ricart MJ; Centellas-Pérez FJ; Solè M; Martorell J; Ríos J; Campistol JM; Diekmann F; Oppenheimer F
Transplantation; 2020 Aug; 104(8):1686-1694. PubMed ID: 32732848
[TBL] [Abstract][Full Text] [Related]
11. Impact of type of calcineurin inhibitor on post-transplant tuberculosis: Single-center study from India.
Agarwal SK; Bhowmik D; Mahajan S; Bagchi S
Transpl Infect Dis; 2017 Feb; 19(1):. PubMed ID: 27775825
[TBL] [Abstract][Full Text] [Related]
12. Corticosteroid-Sparing and Optimization of Mycophenolic Acid Exposure in Liver Transplant Recipients Receiving Mycophenolate Mofetil and Tacrolimus: A Randomized, Multicenter Study.
Saliba F; Rostaing L; Gugenheim J; Durand F; Radenne S; Leroy V; Neau-Cransac M; Calmus Y; Salamé E; Pageaux GP; Duvoux C; Taguieva N; Sinnasse-Raymond G; Sebagh M; Samuel D; Marquet P
Transplantation; 2016 Aug; 100(8):1705-13. PubMed ID: 27454919
[TBL] [Abstract][Full Text] [Related]
13. Short-Term Intensified Dosage Regimen of Mycophenolic Acid is Associated with Less Acute Rejection in Kidney Transplantation from Donation after Circulatory Death.
Peng W; Liu G; Huang H; Wu J; Chen J
Urol Int; 2018; 101(4):443-449. PubMed ID: 30380533
[TBL] [Abstract][Full Text] [Related]
14. The impact of age on patient tolerance of mycophenolate following kidney transplantation.
Rennie TJW; Petrie M; Metcalfe W; Walbaum D; Joss N; Barton E; Marson L; Clancy MJ; Henderson L; Traynor JP; Geddes CG; Phelan PJ
Nephrology (Carlton); 2020 Jul; 25(7):566-574. PubMed ID: 32323461
[TBL] [Abstract][Full Text] [Related]
15. How delayed graft function impacts exposure to mycophenolic acid in patients after renal transplantation.
van Gelder T; Silva HT; de Fijter H; Budde K; Kuypers D; Mamelok RD; Armstrong VW; Oellerich M
Ther Drug Monit; 2011 Apr; 33(2):155-64. PubMed ID: 21383657
[TBL] [Abstract][Full Text] [Related]
16. Cytomegalovirus disease in de novo kidney-transplant recipients: comparison of everolimus-based immunosuppression without prophylaxis with mycophenolic acid-based immunosuppression with prophylaxis.
Manière L; Noble J; Terrec F; Bennani HN; Chevallier E; Janbon B; Germi R; Bugnazet M; Imerzoukene F; Malvezzi P; Rostaing L; Jouve T
Int Urol Nephrol; 2021 Mar; 53(3):591-600. PubMed ID: 33058036
[TBL] [Abstract][Full Text] [Related]
17. Combined introduction of anti-IL2 receptor antibodies, mycophenolic acid and tacrolimus: effect on malignancies after renal transplantation in a single-centre retrospective cohort study.
Braconnier P; Del Marmol V; Broeders N; Kianda M; Massart A; Lemy A; Ghisdal L; Le Moine A; Madhoun P; Racapé J; Abramowicz D; Wissing KM
Nephrol Dial Transplant; 2012 Jun; 27(6):2547-53. PubMed ID: 22123748
[TBL] [Abstract][Full Text] [Related]
18. Diabetes mellitus after kidney transplantation in Japanese patients: The Japan Academic Consortium of Kidney Transplantation study.
Okumi M; Unagami K; Hirai T; Shimizu T; Ishida H; Tanabe K;
Int J Urol; 2017 Mar; 24(3):197-204. PubMed ID: 27862344
[TBL] [Abstract][Full Text] [Related]
19. Safety of Everolimus With Reduced Calcineurin Inhibitor Exposure in De Novo Kidney Transplants: An Analysis From the Randomized TRANSFORM Study.
Tedesco-Silva H; Pascual J; Viklicky O; Basic-Jukic N; Cassuto E; Kim DY; Cruzado JM; Sommerer C; Adel Bakr M; Garcia VD; Uyen HD; Russ G; Soo Kim M; Kuypers D; Buchler M; Citterio F; Hernandez Gutierrez MP; Bernhardt P; Chadban S;
Transplantation; 2019 Sep; 103(9):1953-1963. PubMed ID: 30801548
[TBL] [Abstract][Full Text] [Related]
20. Mycophenolic acid concentrations in peripheral blood mononuclear cells are associated with the incidence of rejection in renal transplant recipients.
Md Dom ZI; Coller JK; Carroll RP; Tuke J; McWhinney BC; Somogyi AA; Sallustio BC
Br J Clin Pharmacol; 2018 Oct; 84(10):2433-2442. PubMed ID: 29974488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
